Jane Street
ENGN icon

Jane Street’s enGene Therapeutics ENGN Stock Holding History

Jane Street’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Buy
156,001
+99,547
+176% +$886K ﹤0.01% 6367
2025
Q4 		$510K Buy
+56,454
New +$452K ﹤0.01% 7645
2025
Q1 		– Sell
-14,038
Closed -$93.4K – 9690
2024
Q4 		$93.4K Buy
+14,038
New +$109K ﹤0.01% 8784

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Jane Street's ENGN Position: Q1 2026 in Review

Jane Street increased its enGene Therapeutics (ENGN) stake by 176% in Q1 2026, buying an estimated $886K and bringing the position to 156,001 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #6367.

Jane Street first reported a position in ENGN in Q4 2024 and has held it in 3 quarters since. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Jane Street held 156,001 shares of enGene Therapeutics worth $1.06M as of Q1 2026.
  • Jane Street bought 99,547 enGene Therapeutics shares in Q1 2026, an estimated $886K.
  • enGene Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #6367 holding.
  • Jane Street first reported a position in enGene Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.